The global prevalence of cardiovascular diseases (CVD) continues to rise steadily, making it
a leading cause of mortality worldwide. Atherosclerosis (AS) serves as a primary driver of …

Recent advances in human genetics, together with a large body of epidemiologic,
preclinical, and clinical trial results, provide strong support for a causal association between …

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic
abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically …

Human studies support a strong association between hypertriglyceridemia and
atherosclerotic cardiovascular disease (CVD). However, whether a causal relationship …

Atherosclerotic cardiovascular disease (ASCVD) is the world's leading cause of death.
ASCVD has multiple mediators that therapeutic interventions target, such as dyslipidaemia …

Approximately 25% of US adults are estimated to have hypertriglyceridemia (triglyceride
[TG] level≥ 150 mg/dL [≥ 1.7 mmol/L]). Elevated TG levels are associated with increased …

Residual cardiovascular risk in patients on optimized LDL-lowering therapy remains a hot
topic. While inflammation explains part of the residual risk, 1–3 triglyceride-rich lipoproteins …

While targeting elevated serum levels of low-density lipoprotein cholesterol has been the
mainstay of atherosclerosis prevention and treatment for decades, the evidence regarding …

Elevations in plasma triglyceride are the result of overproduction and impaired clearance of
triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons …

Lipids and lipoproteins, their metabolism, and their transport are essential contributing
factors of cardiovascular disease (CVD) as they regulate plasma cholesterol concentration …